Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial

被引：11

作者：

Joly, V

Moroni, M

Concia, E

Lazzarin, A

Hirschel, B

Jost, J

Chiodo, F

Bentwich, Z

Love, WC

Hawkins, DA

Wilkins, EGL

Gatell, AJ

Vetter, N

Greenwald, C

Freimuth, WW

De Cian, W

机构：

[1] Hop Bichat, Dept Internal Med, F-75877 Paris 18, France

[2] Osped L Sacco, Div Infect Dis, Milan, Italy

[3] Osped San Raffaele, Div Infect Dis, Milan, Italy

[4] Pharmacia & Upjohn Co, Milan, Italy

[5] Osped S Orsola Malpighi, Div Infect Dis, Bologna, Italy

[6] Osped Borgo Roma, Div Infect Dis, Verona, Italy

[7] Hop Cantonal Univ Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland

[8] Universitatsspital Abt, Div Infect Dis, Zurich, Switzerland

[9] Kaplan Hosp, Clin Immunol, Rehovot, Israel

[10] Ruchill Hosp, Dept Infect & Trop Med, Glasgow G20 9NB, Lanark, Scotland

[11] Kolber Ctr, London, England

[12] N Manchester Grp Hosp, Dept Infect Dis, Manchester, Lancs, England

[13] Hosp Clin & Provencialo, Div Infect Dis, Barcelona, Spain

[14] Wiener Wald Pulm Zentrum Sanatorium, Dept Med, Vienna, Austria

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 11期

关键词：

D O I：

10.1128/AAC.44.11.3155-3157.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

引用

页码：3155 / 3157

页数：3

共 50 条

[1] Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients
Davey, RT
Chaitt, DG
Reed, GF
Freimuth, WW
Herpin, BR
Metcalf, JA
Eastman, PS
Falloon, J
Kovacs, JA
Polis, MA
Walker, RE
Masur, H
Boyle, J
Coleman, S
Cox, SR
Wathen, L
Daenzer, CL
Lane, HC
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (07) : 1657 - 1664
[2] Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients
Cleland, A
Watson, HG
Robertson, P
Ludlam, CA
Brown, AJL
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 12 (01): : 6 - 18
[3] Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine
Chong, KT
Pagano, PJ
ANTIVIRAL RESEARCH, 1997, 34 (01) : 51 - 63
[4] Viral Tropism in Human Immunodeficiency Virus Type 1-Infected Children and Adolescents in Thailand
Arayapong, Natt
Pasomsub, Ekawat
Kanlayanadonkit, Rujikorn
Keatkla, Jiraporn
Techasaensiri, Chonnamet
Phuphuakrat, Angsana
Sungkanuparph, Somnuek
Apiwattanakul, Nopporn
Chaisavaneeyakorn, Sujittra
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (01) : 1 - 6
[5] PROVIRUS LOAD CHANGES IN UNTREATED AND ZIDOVUDINE-TREATED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PATIENTS
LUQUE, F
CARUZ, A
PINEDA, JA
TORRES, Y
LARDER, B
LEAL, M
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02): : 267 - 273
[6] Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients
Karlsson, AC
Gaines, H
Sällberg, M
Lindbäck, S
Sönnerborg, A
JOURNAL OF VIROLOGY, 1999, 73 (07) : 6191 - 6196
[7] ALTERNATING NEVIRAPINE AND ZIDOVUDINE TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PERSONS DOES NOT PROLONG NEVIRAPINE ACTIVITY
DEJONG, MD
LOEWENTHAL, M
BOUCHER, CAB
VANDERENDE, I
HALL, D
SCHIPPER, P
IMRIE, A
WEIGEL, HM
KAUFFMANN, RH
KOSTER, R
SEVILLE, P
ROCKLIN, R
COOPER, DA
LANGE, JMA
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (06): : 1346 - 1350
[8] Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine
Theys, K.
Deforche, K.
Libin, P.
Camacho, R. J.
Van Laethem, K.
Vandamme, A-M
JOURNAL OF GENERAL VIROLOGY, 2010, 91 : 1898 - 1908
[9] Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 trial
Dragsted, UB
Gerstoft, J
Pedersen, C
Peters, B
Duran, A
Obel, N
Castagna, A
Cahn, P
Clumeck, N
Bruun, JN
Benetucci, J
Hill, A
Cassetti, I
Vernazza, P
Youle, M
Fox, Z
Lundgren, JD
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (05): : 635 - 642
[10] Effect of superimposed infections on viral replication in human immunodeficiency virus type 1-infected children
Marchisio, P
Esposito, S
Zanchetta, N
Tornaghi, R
Gismondo, MR
Principi, N
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (08) : 755 - 757

← 1 2 3 4 5 →